Community protocol

Morning Daily

Testosterone

235 lbs

71 in

male

By

John

Weight

GLP-3

Metabolic

Longevity

mot

Metabolic

Weight

cjci

Growth

For research purposes only.

Peptide Mind does not endorse this protocol. This is a user-generated research reference — not for human consumption or therapeutic use.

Log your research schedule

Add this research protocol to your calendar or print a reference copy for your lab records. For research purposes only.

Peptide Protocol Schedule

A day-by-day view of this protocol. Tap any day to see which peptides are active. Circle size reflects how many peptides are scheduled; colored dots below represent individual peptides.

June 2026

Sun

Mon

Tue

Wed

Thu

Fri

Sat

31

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

1

2

3

4

mot

MOTS-c

morning

subcutaneous

2 mg

cjci

CJC-1295 (No Dac)/Ipamorelin

evening

subcutaneous

350 mcg

Daily Dosing Breakdown

A grouped breakdown of which peptides to take throughout this protocol. Consecutive days with the same schedule are combined. Days with no doses are omitted.

Jun 24–25, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jun 26, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jun 27 – Jul 2, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 3, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 4–9, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 10, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 11–16, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 17, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 18–23, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 24, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 25–30, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 31, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 1–6, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 7, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 8–13, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 14, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 15–20, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 21, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 22–27, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 28, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 29 – Sep 3, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Sep 4, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Sep 5–10, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Sep 11, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Sep 12–17, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Sep 18, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Sep 19–24, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Sep 25, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Sep 26 – Oct 1, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 2, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 3–8, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 9, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 10–15, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 16, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 17–22, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 23, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 24–29, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 30, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 31 – Nov 5, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Nov 6, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Nov 7–12, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Nov 13, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Nov 14–19, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Nov 20, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Nov 21–26, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Nov 27, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Nov 28 – Dec 3, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 4, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 5–10, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 11, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 12–17, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 18, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 19–24, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 25, 2026

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 26–31, 2026

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jan 1, 2027

GLP-3 — 4 mg · Morning

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jan 2–6, 2027

MOTS-c — 2 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jan 7, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jan 8, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jan 9–14, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jan 15, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jan 16–21, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jan 22, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jan 23–28, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jan 29, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jan 30 – Feb 4, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Feb 5, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Feb 6–11, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Feb 12, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Feb 13–18, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Feb 19, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Feb 20–25, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Feb 26, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Feb 27 – Mar 4, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Mar 5, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Mar 6–11, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Mar 12, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Mar 13–18, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Mar 19, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Mar 20–25, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Mar 26, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Mar 27 – Apr 1, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Apr 2, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Apr 3–8, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Apr 9, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Apr 10–15, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Apr 16, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Apr 17–22, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Apr 23, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Apr 24–29, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Apr 30, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

May 1–6, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

May 7, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

May 8–13, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

May 14, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

May 15–20, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

May 21, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

May 22–27, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

May 28, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

May 29 – Jun 3, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jun 4, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jun 5–10, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jun 11, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jun 12–17, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jun 18, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jun 19–24, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jun 25, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jun 26 – Jul 1, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 2, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 3–8, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 9, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 10–15, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 16, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 17–22, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 23, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 24–29, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 30, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jul 31 – Aug 5, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 6, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 7–12, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 13, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 14–19, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 20, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 21–26, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 27, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Aug 28 – Sep 2, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Sep 3, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Sep 4–9, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Sep 10, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Sep 11–16, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Sep 17, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Sep 18–23, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Sep 24, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Sep 25–30, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 1, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 2–7, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 8, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 9–14, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 15, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 16–21, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 22, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 23–28, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 29, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Oct 30 – Nov 4, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Nov 5, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Nov 6–11, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Nov 12, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Nov 13–18, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Nov 19, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Nov 20–25, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Nov 26, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Nov 27 – Dec 2, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 3, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 4–9, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 10, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 11–16, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 17, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 18–23, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 24, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 25–30, 2027

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Dec 31, 2027

GLP-3 — 4 mg · Morning

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Jan 1–6, 2028

CJC-1295 (No Dac)/Ipamorelin — 350 mcg · Evening

Weekly Schedule

Day-of-week breakdown for each peptide in this protocol.

Mon

Tue

Wed

Thu

Fri

Sat

Sun

GLP-3

GLP-3

morning

subcutaneous

4 mg

Cycle Duration: 80 weeks

Total Peptide Requirements

The total quantity of each peptide needed to complete this protocol, calculated from dosage and duration.

Weight

GLP-3

Metabolic

GLP-3

4 mg · weekly · Morning

320

Longevity

mot

Metabolic

MOTS-c

2 mg · 7× weekly · Morning

394

Weight

cjci

Growth

CJC-1295 (No Dac)/Ipamorelin

0.35 mg · 7× weekly · Evening

196.7

Know exactly what to draw

Enter your vial concentration and we'll calculate the precise injection volume for every peptide in this protocol.

Calculate dosage

Protocol Body Targets

The biological systems and tissue targets addressed by the 3 peptides in this protocol.

4

Body Targets

3 peptides

Metabolic

Regulates fat metabolism, insulin sensitivity, and energy use.

GLP-3, MOTS-c

Gut

Supports gut lining integrity, digestion, and the gut-brain axis.

GLP-3

Muscle

Enhances muscle growth, repair, and recovery after exercise.

MOTS-c, CJC-1295 (No Dac)/Ipamorelin

Hormones

Influences hormone signaling pathways and endocrine balance.

CJC-1295 (No Dac)/Ipamorelin

Build your own protocol

Create a custom peptide stack tailored to your goals. Add peptides, set dosages, and share it with the community.

Protocol Duration & Timeline

A visual breakdown of each peptide's active window within this protocol. Use this to understand the total cycle length and how each compound's duration compares to the full protocol.

GLP-3
4 mg once per week: 560 days
MOTS-c
2 mg 7x per week: 197 days
CJC-1295 (No Dac)/Ipamorelin
350 mcg 7x per week: 562 days

Protocol Peptides

Each peptide included in this protocol with its dosing amount, frequency, and administration details.

Weight

GLP-3

Metabolic

Preclinical

WeightMetabolic

Longevity

mot

Metabolic

Phase 1

LongevityMetabolic

Weight

cjci

Growth

CJC-1295 (No Dac)/Ipamorelin

Experimental

Build your own protocol

Create a custom peptide stack tailored to your goals. Add peptides, set dosages, and share it with the community.

Browse other protocols

Performance28 days

tori

1

Longevity

mot

Body Recomp29 days

Recovery Protocol

Ryan

2

Healing

bpc

Healing

tb5

Other83 days

Immune and Autoimmune Support

Bryn

3

Longevity

thymo

Healing

kpv

Healing

bpc

Body Recomp83 days

Muscle and Weight Loss Protocol

Bryn

3

Weight

tesa

Weight

GLP-3

Weight

ipa

Frequently asked questions

What is a peptide protocol?

A peptide protocol is a structured research plan that specifies which peptides to study, the quantities and frequencies used in research settings, and the duration of the study period. Research protocols often combine multiple peptides that act on complementary biological pathways—such as tissue repair, cognitive function, or metabolic regulation—to investigate broader or synergistic effects. These protocols are intended for research purposes only and are not a guide for human consumption.

How is peptide dosage calculated from a vial for research?

In a research context, the concentration of a reconstituted peptide solution is calculated by dividing the total peptide content of the vial in micrograms by the volume of bacteriostatic water added in milliliters. For example, a 5mg (5,000 mcg) vial reconstituted with 2mL of BAC water yields a concentration of 2,500 mcg/mL. This information is provided for reference and laboratory calculation purposes only — not as a guide for human use.

How much bacteriostatic water is typically used for peptide reconstitution in research?

Research protocols commonly reconstitute peptide vials with 2mL to 3mL of bacteriostatic water, though the appropriate volume depends on the target concentration needed for a given study. Adding 2mL to a 5mg vial yields a concentration of 2,500 mcg/mL. This information is provided strictly for laboratory and research reference — not as instructions for human use.

How are peptides different from proteins?

Both are composed of amino acids, but peptides are significantly smaller than proteins. Due to their size, peptides can function as precise signaling molecules, binding to specific receptors and triggering targeted biological responses—such as stimulating growth hormone release, promoting tissue repair, or modulating immune activity. These mechanisms are the subject of ongoing scientific research.

Are peptides safe?

Safety profiles vary widely by compound and cannot be generalized. Research considerations include the specific compound, its purity, the quantities studied, the route of administration, and subject health conditions. Some peptides have established clinical trial data; others remain early-stage research chemicals with limited human data. This platform is for research reference only — always review the available peer-reviewed evidence for each compound and consult a qualified medical professional.

Are all peptides medicines?

No. The term "peptide" describes molecular structure—a short chain of amino acids—not regulatory classification. Some peptides are FDA-approved prescription drugs; others are classified as research chemicals and are not approved for human use. Regulatory status varies by compound and jurisdiction. Nothing on this platform should be interpreted as medical or pharmaceutical guidance.

What does peptide reconstitution mean?

Reconstitution is the laboratory process of dissolving a lyophilized (freeze-dried) peptide powder into a sterile carrier liquid—typically bacteriostatic water—to produce a solution of known concentration. The ratio of powder to liquid determines the resulting concentration, which is a key variable in research dosing calculations. This information is provided for research and educational reference only.

How are peptides categorized for research purposes?

Peptides are commonly categorized by their primary biological target or mechanism of action—such as musculoskeletal, neurological, gastrointestinal, or metabolic pathways. Exploring compounds by research area and reviewing the available peer-reviewed literature for each is the recommended starting point for any research protocol design. This platform does not provide personalized recommendations.